Patents Examined by Pancham Bakshi
-
Patent number: 11685710Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.Type: GrantFiled: August 11, 2021Date of Patent: June 27, 2023Assignee: The Board of Regents of The University of Texas SystemInventors: Daniel J. Siegwart, Jason B. Miller
-
Patent number: 11680194Abstract: A method for producing a silicone-based adhesive is disclosed. The method comprises: (1) applying a silicone composition (I) to one surface of a peelable substrate, and then forming a silicone layer (I) by curing or drying the silicone composition (I); and (2) applying a silicone composition (II) to a surface of the silicone layer (I), and then forming the silicone-based adhesive by curing the silicone composition (II). The silicone composition (I) contains a silicone resin. The silicone composition (II) either does not contain the silicone resin or if contained, its content amount is lower than that in the silicone composition (I). The method is useful for producing a silicone-based adhesive with low peel resistance from a peelable substrate even with a low modulus.Type: GrantFiled: April 13, 2018Date of Patent: June 20, 2023Assignee: DOW TORAY CO., LTD.Inventors: Takakazu Hino, Michitaka Suto, Akihiro Nakamura
-
Patent number: 11680053Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.Type: GrantFiled: November 4, 2021Date of Patent: June 20, 2023Assignee: Heptares Therapeutics LimitedInventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Aves, Benjamin Gerald Tehan
-
Patent number: 11666653Abstract: The present invention provides a modified RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand targets an HBV mRNA; all of the nucleotide sugars of the RNAi agent are 2?-modified; and at least one of the sense and antisense strands is conjugated to at least one targeting ligand that comprises two or more building blocks connected to a biantennary or triantennary branched linker, optionally via one or more linking groups.Type: GrantFiled: November 23, 2021Date of Patent: June 6, 2023Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Martin Maier
-
Patent number: 11666592Abstract: The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.Type: GrantFiled: April 28, 2021Date of Patent: June 6, 2023Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Michio Hirano, Caterina Garone, Ramon Marti
-
Patent number: 11667718Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).Type: GrantFiled: June 28, 2021Date of Patent: June 6, 2023Assignee: Vanda Pharmaceuticals Inc.Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
-
Patent number: 11667598Abstract: The invention describes novel mono-hydroxy, di-hydroxy and tri-hydroxy docosapentaenoic acid (DPA) analogues, their preparation, isolation, identification, purification and uses thereof.Type: GrantFiled: August 26, 2019Date of Patent: June 6, 2023Assignee: The Brigham & Women's Hospital Inc.Inventors: Charles N. Serhan, Jesmond Dalli
-
Patent number: 11667910Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).Type: GrantFiled: February 3, 2022Date of Patent: June 6, 2023Assignee: CureVac Manufacturing GmbHInventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
-
Patent number: 11666589Abstract: The present invention relates to compositions comprising at least one of pivarubicin and benzarubicin, or a pharmaceutically acceptable salt thereof, and methods for using the compositions in the treatment of triple negative breast cancer (TNBC) by administering an effective amount of the compositions to a subject. In some instances, the subject is a mammal, including at least one of human, feline, and canine mammals.Type: GrantFiled: March 2, 2021Date of Patent: June 6, 2023Inventors: Leonard Lothstein, Judith Soberman, Tiffany N. Seagroves
-
Patent number: 11660310Abstract: This invention relates to methods and compositions for administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine. In particular, the invention relates to methods for treating cancer, inhibiting degradation of a CDA substrate drug, and reducing DNA methylation in a subject in need thereof comprising administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine.Type: GrantFiled: December 23, 2021Date of Patent: May 30, 2023Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Harold Keer, Mohammad Azab, Aram Oganesian
-
Patent number: 11660306Abstract: The present invention relates to agents and methods for treating autism spectrum disorders, such as Rett Syndrome.Type: GrantFiled: April 8, 2019Date of Patent: May 30, 2023Assignee: Cold Spring Harbor LaboratoryInventors: Nicholas Tonks, Navasona Krishnan
-
Patent number: 11655269Abstract: To provide novel compounds that are promising as prodrug-type anticancer agents, a compound represented by general formula (I) or a salt thereof is provided.Type: GrantFiled: March 4, 2019Date of Patent: May 23, 2023Assignee: THE UNIVERSITY OF TOKYOInventors: Yasuteru Urano, Mako Kamiya, Kento Hayashi
-
Patent number: 11649258Abstract: The present invention provides a palladium(II) complex of formula (1). R12, m, and X are described in the specification. The invention also provides a process for the preparation of the complex, and its use in carbon-carbon and carbon-heteroatom coupling reactions.Type: GrantFiled: February 11, 2021Date of Patent: May 16, 2023Assignee: Johnson Matthey Public Limited CompanyInventors: Thomas Colacot, Ruishan Chow, Andrew Jon DeAngelis
-
Patent number: 11649168Abstract: A high-purity n-tetrasilane purification method includes: introducing a tetrasilane (Si4H10) isomeric mixture into a solidifying purification tank, cooling the tetrasilane (Si4H10) to a predetermined temperature with refrigerant in the solidifying purification tank, maintaining the predetermined temperature between the freezing temperature of the n-tetrasilane (n-Si4H10) and of the i-tetrasilane (i-Si4H10), solidifying the n-tetrasilane (n-Si4H10) in the tetrasilane (Si4H10) isomeric mixture into solid state, and vacuuming the i-tetrasilane (i-Si4H10) from the mixture for separation.Type: GrantFiled: May 8, 2020Date of Patent: May 16, 2023Assignee: Taiwan Speciality Chemicals CorporationInventors: Sung-Yueh Shieh, Teng-Chih Lee
-
Patent number: 11643657Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.Type: GrantFiled: December 17, 2019Date of Patent: May 9, 2023Assignee: WAVE LIFE SCIENCES LTD.Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
-
Patent number: 11633411Abstract: The present invention provides a method of treating sepsis in a subject, comprising administering to the subject an effective amount of a compound of the formula wherein R1 and R2 may be H, OH, protonated phosphate, a phosphate salt, a sugar phosphonate, or a mono-, di- or poly-saccharide, R3 may be OH or a mono-, di- or poly-saccharide, R4, R5, R6 and R7 may be an alkyl or alkenyl chain of up to 13 carbons (for a chain of 16 carbons), and R8, R9, R10 and R11 may be H, OH, or an alkyl or alkenyl ester of up to 16 carbons, or a salt thereof.Type: GrantFiled: October 4, 2017Date of Patent: April 25, 2023Assignee: UNIVERSITY OF MARYLAND, BALTIMOREInventors: Robert K. Ernst, Erin M. Harberts, Alison J. Scott
-
Patent number: 11634381Abstract: Provide herein are compounds with a general chemical structure of: Substituents R1 and R2 independently are H, Cl, F, Br, CH3, CF3, SH, —N(C1-3alkyl)2, —NHC(O)C1-3alkyl, or —NHC(O)C5-7cycloalkyl, substituent R3 is H or C1-3 alkyl and R4 is a bridged cycloalkene such as a bridged cyclohexene or a bridge-substituted cyclohexene. The compounds are therapeutics to treat a cancer, such as breast cancer, or metastatic cancers, to inhibit RUNX2 activity, such as protein expression, in a cancer cell and to increase survival of a subject with breast cancer.Type: GrantFiled: May 3, 2019Date of Patent: April 25, 2023Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans AffairsInventors: Antonino Passaniti, Alexander D. MacKerell, Jr.
-
Patent number: 11634561Abstract: The poor water solubility of high molecular weight chitosan has limited its use in areas such as food and beverage products, post-harvest treatments, cosmetic and pharmaceutical products, medical treatments, and environmental pollution treatments. Disclosed is a high-molecular-weight, solid-state chitosan powder that is completely water-soluble.Type: GrantFiled: November 14, 2016Date of Patent: April 25, 2023Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Witoon Prinyawiwatkul, Zhimin Xu, Yixiao Shen
-
Patent number: 11622950Abstract: The invention provides methods, compositions, and medical kits for treating pancreatic cancer using (i) 6,8-bis(benzylsulfanyl)octanoic acid or a pharmaceutically acceptable salt thereof in combination with (ii) gemcitabine or a pharmaceutically acceptable salt thereof, and (iii) nab-paclitaxel.Type: GrantFiled: July 23, 2019Date of Patent: April 11, 2023Assignee: Cornerstone Pharmaceuticals, Inc.Inventors: Sanjeev Luther, Robert G. L. Shorr
-
Patent number: 11617762Abstract: The present invention provides a synergistic anti-inflammatory composition comprising one more anti-inflammatory agents such as a steroid, non-steroidal anti-inflammatory drug (NSAID) or a cannabinoid in combination with one or more sulfated polysaccharides. The invention is further directed to a method of treating inflammation and inflammatory diseases using said synergistic composition.Type: GrantFiled: December 10, 2017Date of Patent: April 4, 2023Assignee: Seanergy Dermatology Ltd.Inventor: Doron Friedman